Interleukin-1β Promotes Ovarian Tumorigenesis through a p53/NF-κB-Mediated Inflammatory Response in Stromal Fibroblasts
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Cancer has long been considered a disease that mimics an "unhealed wound," with oncogene-induced secretory activation signals from epithelial cancer cells facilitating stromal fibroblast, endothelial, and inflammatory cell participation in tumor progression. However, the underlying mechanisms that orchestrate cooperative interaction between malignant epithelium and the stroma remain largely unknown. Here, we identified interleukin-1β (IL-1β) as a stromal-acting chemokine secreted by ovarian cancer cells, which suppresses p53 protein expression in cancer-associated fibroblasts (CAFs). Elevated expression of IL-1β and cognate receptor IL-1R1 in ovarian cancer epithelial cells and CAFs independently predicted reduced overall patient survival, as did repressed nuclear p53 in ovarian CAFs. Knockdown of p53 expression in ovarian fibroblasts significantly enhanced the expression and secretion of chemokines IL-8, growth regulated oncogene-alpha (GRO-α), IL-6, IL-1β, and vascular endothelial growth factor (VEGF), significantly increased in vivo mouse xenograft ovarian cancer tumor growth, and was entirely dependent on interaction with, and transcriptional up-regulation of, nuclear factor-kappaB (NF-κB) p65. Our results have uncovered a previously unrecognized circuit whereby epithelial cancer cells use IL-1β as a communication factor instructing stromal fibroblasts through p53 to generate a protumorigenic inflammatory microenvironment. Attenuation of p53 protein expression in stromal fibroblasts generates critical protumorigenic functionality, reminiscent of the role that oncogenic p53 mutations play in cancer cells. These findings implicate CAFs as an important target for blocking inflammation in the tumor microenvironment and reducing tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 1×
“As the predominant cellular component of the tumor microenvironment [3], fibroblasts play a critical synergistic role by working with oncogenic cells to facilitate initiation and progression toward clinically recognizable tumor [4,5].”
BackgroundNuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519 · cited 2×
“The NF-κB pathway is well known for the central role it plays in human cancer, in which hyperactivation is a common occurrence due primarily to the promotion this exerts on cell cycle progression, antiapoptosis, angiogenesis, and inflammatory activation [20].”
BackgroundBissell, M. J., & Radisky, D. (2001) · Nature Reviews Cancer · doi:10.1038/35094059 · Cited by 2,180
Tumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996 · cited 1×
“[32] Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G,”
BackgroundKnow thy neighbor: stromal cells can contribute oncogenic signals
Tlsty, T. D., & Hein, P. W. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00156-8 · Cited by 425 · cited 1×
“As the predominant cellular component of the tumor microenvironment [3], fibroblasts play a critical synergistic role by working with oncogenic cells to facilitate initiation and progression toward clinically recognizable tumor [4,5].”
BackgroundYang, G., Rosen, D. G., Zhang, Z., Bast, R. C., Mills, G. B., Colacino, J. A., Mercado-Uribe, I., & Liu, J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605752103 · Cited by 341 · cited 4×
“[24] Yang G, Rosen DG, Zhang Z, Bast RC Jr, Mills GB, Colacino JA, Mercado-”
BackgroundMethodSelf-citationSelective Evolution of Stromal Mesenchyme with p53 Loss in Response to Epithelial Tumorigenesis
Hill, R., Song, Y., Cardiff, R. D., & Van Dyke, T. (2005) · Cell · doi:10.1016/j.cell.2005.09.030 · Cited by 324 · cited 1×
“[39] Hill R, Song Y, Cardiff RD, and Van Dyke T (2005).”
BackgroundEvidence for Nonautonomous Effect of p53 Tumor Suppressor in Carcinogenesis
Kiaris, H., Chatzistamou, I., Trimis, G., Frangou-Plemmenou, M., Pafiti-Kondi, A., & Kalofoutis, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3791 · Cited by 128
Aylon, Y., & Oren, M. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.002 · Cited by 106 · cited 1×
“In addition to the wellknown effect of p53 in maintaining genomic integrity despite DNA damage or instability through apoptosis regulation [11], p53 is known to function in regulation of inflammation [12].”
Background
Cited by
Ahmed, N., & Stenvers, K. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00256 · Cited by 482
Interleukin-1 Beta—A Friend or Foe in Malignancies?
Bent, R., Moll, L., Grabbe, S., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082155 · Cited by 444
Jiang, G.-M., Tan, Y., Wang, H., Peng, L., Chen, H.-T., Meng, X.-J., Li, L.-L., Liu, Y., Li, W.-F., & Shan, H. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0944-z · Cited by 365
Rébé, C., & Ghiringhelli, F. (2020) · Cancers · doi:10.3390/cancers12071791 · Cited by 337
p53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
“Loss of p53 in CAFs, mesenchymal stem cells (MSCs) or hepatic stellate cells (HSCs) promotes the growth of many cancer cell types including breast, prostate, ovarian and liver cancers (Addadi et al., 2010; Huang et al., 2014; Narendran et al., 2003; Ren et al., 2012; Schauer et al., 2013).”
Background
Metadata
- Authors
- Schauer, I. G., Zhang, J., Xing, Z., Guo, X., Mercado-Uribe, I., Sood, A. K., Huang, P., & Liu, J.
- Venue
- Neoplasia
- Publisher
- Elsevier BV
- Published
- 2013-04
- Volume
- 15
- Issue
- 4
- Pages
- 409-IN18
- ISSN
- 1476-5586 (ISSN-L)
- OpenAlex
- W1960216149
- Cited by
- 97
- References
- 9
- FWCI
- 10.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.